Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: Results from three randomized placebo-controlled phase III trials: Part I

David M. Pariser*, Kenneth B Gordon, Kim A. Papp, Craig L. Leonardi, Paul Kwon, Peter G. Compton, Amy Chen Rundle, Patricia A. Walicke, Mark Lebwohl

*Corresponding author for this work

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Background: Effective psoriasis therapies are needed for long-term symptom control. Assess efalizumab (Raptiva®) efficacy in a large cohort of psoriasis patients. Methods: Data from three Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter studies were pooled. Patients (n = 1,651) with moderate to severe plaque psoriasis received 12 weeks of subcutaneous efalizumab 1 or 2 mg/kg/wk or placebo. Results: All efficacy measures reached statistical significance within each of the individual studies (p < 0.001) and overall. More efalizumab-treated patients achieved ≥ 75% and ≥ 50% Psoriasis Area and Severity Index (PASI) improvement at week 12 than did placebo-treated patients (27.8% vs 3.8% [p < 0.001] and 56.1% vs 14.6% [p < 0.001], respectively). Significant PASI improvements occurred as early as week 2 (12.5% vs 7.9%, p =0.0001). Adverse events were generally mild to moderate. Conclusion: Efalizumab resulted in early and significant improvement for all efficacy endpoints and was well tolerated in patients with moderate to severe chronic plaque psoriasis.

Original languageEnglish (US)
Pages (from-to)303-312
Number of pages10
JournalJournal of Cutaneous Medicine and Surgery
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint Dive into the research topics of 'Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: Results from three randomized placebo-controlled phase III trials: Part I'. Together they form a unique fingerprint.

  • Cite this

    Pariser, D. M., Gordon, K. B., Papp, K. A., Leonardi, C. L., Kwon, P., Compton, P. G., Rundle, A. C., Walicke, P. A., & Lebwohl, M. (2005). Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: Results from three randomized placebo-controlled phase III trials: Part I. Journal of Cutaneous Medicine and Surgery, 9(6), 303-312. https://doi.org/10.1007/s10227-005-0116-1